Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 15, Issue 3, 2016, Pages 380-385

  Qvist, Tavs ^a   Taylor Robinson, David ^b   Waldmann, Elisabeth ^c   Olesen, Hanne Vebert ^d   Hansen, Christine Rønne ^a   Mathiesen, Inger Hee ^a   Høiby, Niels ^a   Katzenstein, Terese L ^a   Smyth, Rosalind L ^e   Diggle, Peter J ^f   Pressler, Tania ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Abscessus; CF; Gram negative; Lung function; NTM

Indexed keywords

ACHROMOBACTER XYLOSOXIDANS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; DANISH CITIZEN; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; REGISTER; ADULT; CHRONIC DISEASE; DENMARK; ISOLATION AND PURIFICATION; LUNG; LUNG FUNCTION TEST; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADULT; CHRONIC DISEASE; CYSTIC FIBROSIS; DENMARK; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RESPIRATORY FUNCTION TESTS;

EID: 84947344611     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.09.007     Document Type: Article

References (39)

1. Konstan M.W., Wagener J.S., Vandevanter D.R., Pasta D.J., Yegin A., Rasouliyan L., et al. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros 2012, 11:405-411.
2. Kerem E., Viviani L., Zolin A., MacNeill S., Hatziagorou E., Ellemunter H., et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 2014, 43:125-133.
3. Koch C., Høiby N. Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cyst Fibros Copenhagen Thorax 1991, 46:385-386. [discussion 389-90].
4. Koch C., Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993, 341:1065-1069.
5. Dalbøge C.S., Pressler T., Høiby N., Nielsen K.G., Johansen H.K. A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF. J Cyst Fibros 2013, 12:42-48.
6. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32:277-287.
7. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100.
8. Taylor-Robinson D., Whitehead M., Diderichsen F., Olesen H.V., Pressler T., Smyth R.L., et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax 2012, 67:860-866.
9. Taylor-Robinson D.C., Smyth R.L., Diggle P.J., Whitehead M. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study. Lancet Respir Med 2013, 1:121-128.
10. Dalbøge C.S., Hansen C.R., Pressler T., Høiby N., Johansen H.K. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 2011, 10:318-325.
11. Griffith D.E., Aksamit T., Brown-Elliott B.a, Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
12. Olivier K.N., Weber D.J., Lee J.-H.H., Handler A., Tudor G., Molina P.L., et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003, 167:835-840.
13. Esther C.R., Esserman D.A., Gilligan P., Kerr A., Noone P.G., Esther C.R. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
14. Martiniano S.L., Sontag M.K., Daley C.L., Nick J.A., Sagel S.D. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014, 11:36-44.
15. Nessar R., Cambau E., Reyrat J.M., Murray A., Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012, 67:810-818.
16. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
17. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993, 15:75-88.
18. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
19. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977, 1-96.
20. Pressler T., Bohmova C., Conway S., Dumcius S., Hjelte L., Høiby N., et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 2011, 10(Suppl. 2):S75-S78.
21. Pincikova T., Nilsson K., Moen I.E., Fluge G., Hollsing A., Knudsen P.K., et al. Vitamin D deficiency as a risk factor for cystic fibrosis-related diabetes in the Scandinavian Cystic Fibrosis Nutritional Study. Diabetologia 2011, 54:3007-3015.
22. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics 1982, 38:963-974.
23. Leung J.M., Olivier K.N. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med 2013, 19:662-669.
24. Catherinot E., Roux A.L., Vibet M.A., Bellis G., Ravilly S., Lemonnier L., et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013, 12:74-80.
25. Qvist T., Gilljam M., Jönsson B., Taylor-Robinson D., Jensen-Fangel S., Wang M., et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 2015, 14:46-52.
26. HILL A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
27. Rønne Hansen C., Pressler T., Høiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006, 5:245-251.
28. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.Ø., Bjarnsholt T., Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010, 9:51-58.
29. Hansen C.R., Pressler T., Koch C., Høiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005, 4:35-40.
30. Lipuma J.J. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 2005, 11:528-533.
31. Com G., Carroll J.L., Castro M.M., Tang X., Jambhekar S., Berlinski A. Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis. J Pediatr 2014, 164:832-838.
32. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:955-959.
33. Hansen C.R. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen. Curr Opin Pulm Med 2012, 18:628-631.
34. Waters V., Atenafu E.G., Salazar J.G., Lu A., Yau Y., Matukas L., et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 2012, 11:8-13.
35. De Baets F., Schelstraete P., Van Daele S., Haerynck F., Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007, 6:75-78.
36. Lambiase A., Catania M.R., Del Pezzo M., Rossano F., Terlizzi V., Sepe A., et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011, 30:973-980.
37. Frederiksen B., Lanng S., Koch C., Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996, 21:153-158.
38. Diggle P., Zeger S.L., Liang K.-Y., Heagerty P. Analysis of longitudinal data. Oxf Stat Sci Ser 2002, 2nd:379.
39. Molenberghs G. Applied longitudinal analysis. J Am Stat Assoc 2005, 100:709-710.